Agennix

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Agennix sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Agennix: 13 sponsored US clinical trials, none currently recruiting.

Agennix sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage).

Top-decile sponsor footprint

Agennix ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

7 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (53.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

COMPLETED Phase 3

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
COMPLETED Phase 2

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

NCT00630656
TERMINATED Phase 1

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

NCT00480623
TERMINATED Phase 1

Study of Satraplatin (JM-216) in Combination With Docetaxel

NCT00125411
TERMINATED Phase 3

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

NCT00450970
COMPLETED Phase 2

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
TERMINATED Phase 1

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

NCT00329329
TERMINATED Phase 1

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

NCT00313456
COMPLETED Phase 2

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00268970
COMPLETED Phase 2

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

NCT00265655
COMPLETED Phase 2

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

NCT00095186
TERMINATED Phase 1

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

NCT00093132
COMPLETED Phase 3

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 5
Phase 3 3

How the Agennix early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 7 completed (54%).

Phase mix: 3 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Therapeutic area indexing for this sponsor is limited in the public registry.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Agennix: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Agennix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share AgennixAdaptimmuneAkili Interactive LabsAlumisAndrei Iagaru10xBio22nd Century Group23andMe3-C Institute for Social Development
Agennix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Agennix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Agennix page

13 registered trials is a research-attention snapshot, not an endorsement of Agennix or any single study.

  • None of Agennix's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Agennix pipeline card: 13 registered trials from official public datasets.Report a data error.